No annual revenue total was found in PROMIS NEUROSCIENCES INC.'s SEC filings.
Promis Neurosciences Inc. (PMN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-42.23M
-401.1% vs year-ago TTM
Operating cash flow (TTM)
$-42.11M
-74.2% vs year-ago TTM
Free cash flow
$-17.04M
EPS (TTM)
$-8.51
-904.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
8.97M
-72.6% vs prior year
Net cash
$12.63M
FY 2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PMN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Toronto, Ontario, Canada
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1374339
- Former names
- AMORFIX LIFE SCIENCES LTD (until Nov 3, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$40.2M | -$16.8M | -$14.3M | -$23.4M |
| Net income | -$39.7M | $2.8M | -$13.2M | -$18.1M |
| Diluted EPS | -$22.61 | $2.63 | -$1.07 | -$2.41 |
| Operating cash flow | -$28.1M | -$27.2M | -$10.8M | -$17.0M |
| Free cash flow | — | — | — | -$17.0M |
| Total assets | $9.2M | $18.9M | $13.6M | $6.9M |
| Total liabilities | $10.4M | $2.4M | $9.9M | $8.3M |
| Stockholders' equity | -$1.3M | $16.5M | $3.8M | -$1.3M |
| Cash and investments | $6.2M | $13.3M | $12.6M | $5.9M |
| Total debt | — | — | $0 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 20, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
All 373 Promis Neurosciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.